Romidepsin (FK228, Depsipeptide)

For research use only. Not for use in humans.

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

97 publications

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Romidepsin (FK228, Depsipeptide) has been cited by 97 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NIr4O2tE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUKyMlUuOTVibl2= MV:3NkBp NV7kNVk5cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NG\6dXIzPTd7MEmwOy=>
U2932  NI\5U3NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkflNk42NTF3IH7N Mn\IO|IhcA>? M36yPYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NICzS2QzPTd7MEmwOy=>
OCI-LY7 NVv3R2NuS2WubDDWbYFjcWyrdImgRZN{[Xl? M4HjNVIvPS1zNTDuUS=> MVq3NkBp M3v0bolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? Mn3tNlU4QTB7MEe=
Farage NFPvVWRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWf0PZdxOi53LUG1JI5O Mn7FO|IhcA>? M1PVeYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M1;sflI2PzlyOUC3
LY7/EBV NV\STZpPS2WubDDWbYFjcWyrdImgRZN{[Xl? MnK4Nk42NTF3IH7N MXO3NkBp NIXzWZlqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NXu2eXJWOjV5OUC5NFc>
U2932/EBV NX3TcIg6S2WubDDWbYFjcWyrdImgRZN{[Xl? M3rXV|IvPS1zNTDuUS=> NWOyOpJ6PzJiaB?= NInTTHVqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NFy1R2czPTd7MEmwOy=>
HCT116 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVu1MVUxODBibl2= NGrMNYIzPCCq M3rkS2ROW09? MULpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= M2f4OVI2PDl{NUG1
ACH-2 NHGzb2hHfW6ldHnvckBCe3OjeR?= MkL1NU06KG6P NIDWfXIzPCCq NGrBNnJqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NWDIRlc4OjVzNEm0Olc>
MCF-10A NGm2PGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMUhCtVAvODFibl2= M3HwWFI1QTV2OEW2
MCF-7 NF3GSVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\vcWlEPTB;MT6xNOKyOC5{MDDuUS=> M1fhOlI1QTV2OEW2
SK-BR-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fXeWlEPTB;MT6wNOKyOC5|NTDuUS=> NYDaSolJOjR7NUS4OVY>
MDA-MB-231 NVfIVW5TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW4W2IxUUN3ME2wMlY5yrFyLkG0JI5O Mln4NlQ6PTR6NU[=
PC3 M3LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;HNGlEPTB;MT62OeKyOC5|NTDuUS=> MV:yOFk2PDh3Nh?=
HCT116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrZOHdRUUN3ME2xMlAxyrFyLkCwJI5O NF23dngzPDl3NEi1Oi=>
HCT116-p21-/- MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwMkdCtVAvOzdibl2= MVGyOFk2PDh3Nh?=
S1 M4\3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr1TWM2OD15Lk[3xtExNjJ7IH7N MYGyOFk2PDh3Nh?=
SW620 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXSTWM2OD1yLkmzxtExNjJ7IH7N NX;ZRmY2OjR7NUS4OVY>
LOX-IMVI MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTHW5RnUUN3ME2wMlg4yrFyLkCzJI5O MYKyOFk2PDh3Nh?=
UACC-62 NHPQSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorETWM2OD1yLkW2xtExNjF4IH7N MV[yOFk2PDh3Nh?=
MDA-MB-435 M3\PUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwOUFCtVAvODZibl2= Ml7jNlQ6PTR6NU[=
SF-295 NYfZS3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL5TWM2OD1yLki4xtExNjF3IH7N MkDFNlQ6PTR6NU[=
A549 NV;JWnllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELoVohKSzVyPUGuNlbDuTBwMkSgcm0> NXvSWI8{OjR7NUS4OVY>
H460 M1fodmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XETWlEPTB;Mj61POKyOC56MDDuUS=> NV7HXGFZOjR7NUS4OVY>
EKVX MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD1zLkOzxtExNjN2IH7N NGjwToMzPDl3NEi1Oi=>
H146 NWHLd2JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[5OXR{UUN3ME2wMlIzyrFyLkC3JI5O NEXxW2MzPDl3NEi1Oi=>
H526 NV6zNmxuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuTWM2OD1yLkG1xtExNjB|IH7N MYeyOFk2PDh3Nh?=
HuT-78 MlW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknLTWM2OD1zLkezxtExNjR2IH7N NUDHOIJmOjR7NUS4OVY>
HA NUO3WpY1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOwMlYzPS1zMH7N MmnBOFghcA>? NUeybXhXcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? NV\0Z3lPOjR5N{G1NVA>
MS-275 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXSwMlYzPS1zMH7N NV7LXJhiPDhiaB?= NXHjT4N1cW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? M3qxXVI1PzdzNUGw
CD4 T Mk\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TCVlQ5KGh? NVXnWZJ7TUN3ME20MlXDuTFwMDDuUS=> MlrpNlQ4OjJ2NUS=
CD4 T MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\aOFghcA>? MWPDR|UxRTFyN9MxNVI3KG6P MWqyOFczOjR3NB?=
CD4+ T M3LGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7JZo1GSzVyPUOgcm0> NYriUmtuOjR2OUWxNFU>
A549 NYjIfXR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXZclAyOOLCk{GwNOKhdk1? NVLJNYhxOjRxM{[vOFghcA>? MkLXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NWXob4I4OjR2OEW3PVk>
JJN3 M3;JVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjtNlQwPDhiaB?= M{fEVmVEPTB:MfMAjY5OQyB2OPMAjYg> MnzQNlQxOzBzNUC=
OPM-2 NIrUTZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P5XVI1NzR6IHi= M{PM[GVEPTC|PUJihKlvVTtiNElihKlp MoS1NlQxOzBzNUC=
RPMI-8226 Mm\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7jbJd6OjRxNEigbC=> MkPISWM2OHN;MT645qCKdk19IES45qCKcA>? MVuyOFA{ODF3MB?=
U266 NWrBOmdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;heJYzPC92ODDo NEX5XGlGSzVyc{2xNQKBkW6POzC0PQKBkWh? M3j3N|I1ODNyMUWw
CA46 NH76TJBCeG:ydH;zbZMhSXO|YYm= M1niUlYhcA>? NXjvXmxUcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MX6yN|k3PjF4NB?=
DG75 M1\QeGFxd3C2b4Ppd{BCe3OjeR?= MVi2JIg> M3GxSYlv\HWlZYOgco8h[XCxcITvd4l{ NYLBbHFHOjN7Nk[xOlQ>
Ramos MXrBdI9xfG:|aYOgRZN{[Xl? M{LrOFYhcA>? MWPpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MUmyN|k3PjF4NB?=
ST486 MVPBdI9xfG:|aYOgRZN{[Xl? Mlj6OkBp M4rPSIlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> Ml[xNlM6PjZzNkS=
HuT78 M3HjWGFxd3C2b4Ppd{BCe3OjeR?= Mmj3NU8yOC9zMECgcm0> MXS0PEBp MlfFbY5lfWOnczDhdI9xfG:|aYOgZZQhOSCwTR?= MV2yN|U{Ojd|Mh?=
DpVp35 Mn;ZRZBweHSxc3nzJGF{e2G7 M{[weVEwOTBxMUCwJI5O Mm\WOFghcA>? NY\nVWRQcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MYiyN|U{Ojd|Mh?=
DpVp50 NEXKc21CeG:ydH;zbZMhSXO|YYm= NH7XdZQyNzFyL{GwNEBvVQ>? Mn:yOFghcA>? NETTVWtqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MlTGNlM2OzJ5M{K=
DpP75  MVrBdI9xfG:|aYOgRZN{[Xl? NGjkcJYyNzFyL{GwNEBvVQ>? NWj0PXJLPDhiaB?= Ml\IbY5lfWOnczDicJVvfCCjcH;weI9{cXN? NIO4dJIzOzV|MkezNi=>
SKOV-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXOx5qCUOjCwTR?= MVO3NkBp Mnu1SG1UVw>? M2HIZpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MoS3NlMxOTB|NEi=
Brca1 WT NVTxbWVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfENgKBmzJybl2= M1jUclczKGh? MljVSG1UVw>? Mo\pdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MoHxNlMxOTB|NEi=
Brca1 Null NVS4d4l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Dt[FHjiJN{MH7N Mke2O|IhcA>? MW\EUXNQ M4DSd5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NIHEbYkzOzBzMEO0PC=>
OVCAR-8  MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWx5qCUOjCwTR?= MnfyO|IhcA>? Mkn0SG1UVw>? M4XvVZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NXPa[mJMOjNyMUCzOFg>
NCI/ADR-RES M{TmW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ftNlHjiJN{MH7N MWi3NkBp NFP4RmxFVVOR NHPWV2lz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NIDrfpMzOzBzMEO0PC=>
HCT116 M{\wNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzod|dGPSCwTT21NEDPxE1? MXuyOEBp NF;DNG5FVVOR MVzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NGnF[WIzOjl{NEm1PC=>
RKO M{XVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3vOUBvVS13MDFOwG0> NUHWUW1WOjRiaB?= NWnxd|VTTE2VTx?= MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M17VOlIzQTJ2OUW4
CO115 NHXISZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTMWm1JPSCwTT21NEDPxE1? Mo\GNlQhcA>? NX7lUVg5TE2VTx?= MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> M1TVWlIzQTJ2OUW4
HFS NVznVnpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDrOUBvVQ>? Mnm5NlQwPDhxN{KgbC=> MWjpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nLXTldIVv\GWwdHz5 NID4R2gzOjFyNkK4Ni=>
LNCaP NVrYPWdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXyPVQ2KG6P NVPLWotyOjRxNEivO|IhcA>? M122dolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NW\pNYFJOjJzME[yPFI>
A549 M{\LfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jFWlUhdk1? MVeyOE81QC95MjDo NWfpNGtGcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NFPBN20zOjFyNkK4Ni=>
697  M3W4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zzUGlEPTEkgJm95qCKOi53wrDuUS=> M3zDeVIyPTN6MkG2
697-R MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|Ux6oDLPfMAjVgvPsLibl5CpC=> M3vPVlIyPTN6MkG2
HUT78 M{DwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFibl2= NUni[YJUOjFzOUi1OFU>
THJ-16T MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnsOpIyKG6P MV2yOEBp MnrJbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NX7IPFlQOjB6MUC1Olg>
HCT116 NITmeIRHfW6ldHnvckBCe3OjeR?= NH\xO2UzOCCwTR?= MnfwPEBp M3joT41w\HWuYYTld{B1emGwc3PybZB1KGyndnXsd{Bnd3JiaIXu[JJm\HNib3[g[4Vv\XNiaX6g[Yl1cGW{IHTpdoVkfGmxbh?= NXfJPINEOjB5M{m0OVQ>
B104  Ml7hSpVv[3Srb36gRZN{[Xl? MlfmNkBvVQ>? M132NVI1NzR6L{eyJIg> NHyweYFqdmO{ZXHz[ZMhfGinIIP1doZi[2ViZYjwdoV{e2mxbjDv[kBETDJywrC= M160XVIxPjh4NUC1
HL-60  MX7DfZRwfG:6aXPpeJkhSXO|YYm= NIXt[|YyNTVyMDDuUS=> NEnBOGEzPCCq MmHzbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NV\OV5JPOjB4MkSxOlM>
HP100 NIqzTFREgXSxdH;4bYNqfHliQYPzZZk> MVyxMVUxOCCwTR?= MkHSNlQhcA>? MmLvbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? M4K4VVIxPjJ2MU[z
HL-60  Ml64SpVv[3Srb36gRZN{[Xl? M4fYd|ExKG6P NIHsfZM1NzZxMU[gbC=> MUDpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? MUeyNFYzPDF4Mx?=
HP100 M3fUTGZ2dmO2aX;uJGF{e2G7 MmH6NVAhdk1? MVK0M|YwOTZiaB?= M{jLdYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= M13WNFIxPjJ2MU[z
HL-60  MoLhSpVv[3Srb36gRZN{[Xl? M{H5dlExNTVyMDDuUS=> NH3xfIc1KGh? MkC4[IVkemWjc3XzJJRp\SCqaYP0c45mKGSnYXPleJlt[XOnIDjISGFEMSCjY4Tpeol1gcLi M1raXVIxPjJ2MU[z
HP100 NI[2fWtHfW6ldHnvckBCe3OjeR?= Mn\ZNVAuPTByIH7N NV;sTmJHPCCq NULwT|cx\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMg M4H2OVIxPjJ2MU[z
11z M4DHXWtqdmG|ZTDBd5NigQ>? MXyzMVExOCCwTR?= NITNXFNz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NFjoUHgzODZyNUG0OC=>
SKOV-3 NXjRbXhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXH[GNQPC96L{G2JI5O NH3PZlY1QCCq MmL4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MXuyNFQxPDV4NB?=
OVCAR-3 NX3FeIR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LDfVQwQC9zNjDuUS=> M334T|Q5KGh? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NFHnRoQzODRyNEW2OC=>
HBL-2 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULwWIREOi1zMDDuUS=> MWOyOEBp NYfxeZZyUUN3ME20MlMhdk1? NXv3enU4OjByNkiwPFA>
Jeko-1 MmezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYiyMVUxKG6P MnOwNlQhcA>? NVuxRYU4UUN3ME2xNUBvVQ>? M2KxPVIxODZ6MEiw
Granta-519 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\MSlUuPDBibl2= MlftNlQhcA>? M3TxXGlEPTB;NUiuOUBvVQ>? M3vJ[VIxODZ6MEiw
L1236 NEDoe3ZEgXSxdH;4bYNqfHliQYPzZZk> NVnsR2ZZOSCwTT2xNFAh|ryP NGS4XY41QCCq MmPBSWM2OD1yLkC3JO69VQ>? Ml7lNVkzOzN2N{C=
L428 NV\EN3d4S3m2b4TvfIlkcXS7IFHzd4F6 MnjPNUBvVS1zMECg{txO MUW0PEBp MWjFR|UxRTBwNEOg{txO NGnFSpQyQTJ|M{S3NC=>
KM-H2 MnfQR5l1d3SxeHnjbZR6KEG|c3H5 NWLIWpUyOSCwTT2xNFAh|ryP NIfLdYU1QCCq Mke4SWM2OD1yLkW4JO69VQ>? M375[|E6OjN|NEew
L540Cy NVvhfYY5S3m2b4TvfIlkcXS7IFHzd4F6 M3f6TlEhdk1vMUCwJO69VQ>? MYC0PEBp MUXFR|UxRTBwMU[g{txO M3PhelE6OjN|NEew
G401 NHvm[2pHfW6ldHnvckBCe3OjeR?= MlzBNVAhdk1? M3G3e|I1NzR6L{eyJIg> NILCbnVFVVOR M1nFTIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> MlXlNVkzOjF3OE[=
STM91-01 M{jhSmZ2dmO2aX;uJGF{e2G7 NGm0fowyOCCwTR?= MnjBNlQwPDhxN{KgbC=> MXrEUXNQ MXzpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NWjjU3FsOTl{MkG1PFY>
SJSC  M{jXR2Z2dmO2aX;uJGF{e2G7 M1LNWlExKG6P Mlq1NlQwPDhxN{KgbC=> NGTnXZRFVVOR MXnpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= NWfYfWVsOTl{MkG1PFY>
BT16  MoDOSpVv[3Srb36gRZN{[Xl? M2m2TFExKG6P Mnv4NlQwPDhxN{KgbC=> MX\EUXNQ MXTpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M{HJNVE6OjJzNUi2
NCI-H1299 NUXpZ2hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojUTWM2OD12LkdCtVAvOiCwZz;tcC=> M4fXWVE6OTd7OEmw
NCI-2882 M{HvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjDZmVKSzVyPUGuOuKyOC5yNDDu[{9udA>? NEG0N3cyQTF5OUi5NC=>
HCC95 NUOzRYxYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1[WlEPTB;Mj61xtExNjB3IH7nM41t NISzRZcyQTF5OUi5NC=>
NCI-H23 M{Phdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwOdMxNE4zKG6pL33s MVWxPVE4QTh7MB?=
NCI-H157 NX;l[5B7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfSenlKSzVyPUGuOuKyOC5yMjDu[{9udA>? M2XMXVE6OTd7OEmw
NCI-H460 NVHxVmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwMdMxNE4xPyCwZz;tcC=> M4Cx[|E6OTd7OEmw
NCI-H1975 M1S2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXpUWtKSzVyPUGuN:KyOC5yNDDu[{9udA>? MVmxPVE4QTh7MB?=
NCI-H820 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPBTWM2OD1{LkVCtVAvOSCwZz;tcC=> NVLQTmtVOTlzN{m4PVA>
NCI-H1650 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r3XmlEPTB;ND65xtExNjNibnevcYw> MkTRNVkyPzl6OUC=
DTC1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwNUGgcm0> NF3KNGQyQDV4NkK0Oi=>
KAO MlL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLwSVA1UUN3ME2wMlkyKG6P M1LFPVE5PTZ4MkS2
SU-CCS-1 NXzsO5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwOEmgcm0> NFzsWWYyQDV4NkK0Oi=>
SYO-1 MkWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjXeVNKSzVyPUCuOlchdk1? MkmyNVg2PjZ{NE[=
FUJI NWnMVmlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DVNmlEPTB;MT6zNUBvVQ>? MmrsNVg2PjZ{NE[=
SKNMC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XOe2lEPTB;MT6xO{BvVQ>? MmPNNVg2PjZ{NE[=
402-91 NITjcJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX30bY9qUUN3ME2xMlI3KG6P MYmxPFU3PjJ2Nh?=
1765-92 M3vCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwN{egcm0> NGXvOlUyQDV4NkK0Oi=>
JN-DSRCT-1 M3PRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\F[JhvUUN3ME2xMlI2KG6P NF;KenAyQDV4NkK0Oi=>
NMS-2PC NUnDVpBxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPCS4hnUUN3ME2wMlgyKG6P M1PBNFE5PTZ4MkS2
HL60 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTFwOE[gcm0> M2LQ[FE5PTZ4MkS2
A549 NYnHd2dHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfFTWM2OD1|LkK0JI5O NX;2c4VLOTh3Nk[yOFY>
SW480 NInPNGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfUTWM2OD1{Lk[5JI5O NHPPVlQyQDV4NkK0Oi=>
MCF7 NFe4TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnxTWM2OD1|LkW1JI5O NF6yNmUyQDV4NkK0Oi=>
PC-3 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3:wNWlEPTB;Mj61NUBvVQ>? M1PneFE5PTZ4MkS2
MMRU NGLaW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzxS3dmUUN3ME2yMlU4KG6P MkLHNVg2PjZ{NE[=
Hs68 NV\PSHliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L1ZWlEPTB;PkGwJI5O MV2xPFU3PjJ2Nh?=
hMSC-001F NYjIOIU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzXTWM2OD1-MUCgcm0> MV6xPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

- Collapse

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

- Collapse
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting Drug: Tenalisib|Drug: Romidepsin T Cell Lymphoma Rhizen Pharmaceuticals SA March 12 2019 Phase 1|Phase 2
NCT02616965 Recruiting Drug: Romidepsin|Drug: Brentuximab vedotin Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics Inc.|Celgene Corporation February 22 2017 Phase 1
NCT02616874 Completed Drug: MVA.HIVconsv vaccine|Drug: Romidepsin HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN Checkpoint February 2016 Phase 1
NCT03141203 Recruiting Drug: Romidepsin|Drug: Carfilzomib Peripheral T Cell Lymphoma University of Birmingham|Bloodwise|Celgene|Amgen July 13 2015 Phase 1|Phase 2
NCT02393794 Recruiting Drug: Romidepsin|Drug: Cisplatin|Drug: Nivolumab Triple-Negative Breast Cancer|Breast Cancer Priyanka Sharma|Celgene Corporation|Bristol-Myers Squibb|University of Kansas Medical Center July 17 2015 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID